Review highlights over 40 PD-L1-targeting radiotracers, with non-invasive imaging feasible in 100+ cancer patients
Background
Detecting Programmed death-ligand 1 (PD-L1) expression is crucial for guiding cancer immunotherapy, as its high expression in tumor cells and the tumor microenvironment mediates immune evasion. Conventional methods like immunohistochemistry (IHC) suffer from invasiveness, temporal and spatial heterogeneity, and lack dynamic monitoring capabilities. This creates a significant gap for precise patient selection and treatment response prediction. Molecular imaging offers a non-invasive, quantitative, and whole-body approach to assess PD-L1 expression, addressing these limitations and becoming a focal point in precision oncology.
Study Design
This paper systematically reviewed the development trajectory of PD-L1-targeting radiotracers, encompassing various molecular types including monoclonal antibodies, peptides, nanobodies, aptamers, and small molecules. The review summarized their targeting performance, pharmacokinetics, imaging efficacy, and safety profiles across both preclinical and clinical studies. It also compared the advantages and suitable applications of different tracer types, and analyzed current challenges in the field, such as the absence of standardized evaluation criteria and issues with clinical translation.
Results
The review identified that > 40 PD-L1-targeting tracers have undergone preclinical or clinical validation, demonstrating the breadth of research in this area. Non-invasive imaging using these tracers has been shown to be feasible in over 100 cancer patients, providing early evidence for their clinical utility. The paper compared the diverse targeting performance and pharmacokinetics of different tracer types, from large monoclonal antibodies to smaller peptides and small molecules, highlighting their varied applications. Challenges identified include the lack of evaluation standards, issues with tumor heterogeneity, insufficient clinical translation, and a scarcity of multicenter data. > Early data strongly support further in-depth research and clinical translation in the field of PD-L1-targeted molecular imaging, underscoring its potential.
Key Findings
- Over 40 PD-L1-targeting radiotracers have undergone preclinical or clinical validation.
- Non-invasive imaging of PD-L1 expression is feasible in over 100 cancer patients.
- The review compared targeting performance, pharmacokinetics, and safety of different tracer types (antibodies, peptides, nanobodies, aptamers, small molecules).
- Key challenges include lack of evaluation standards, tumor heterogeneity, and insufficient clinical translation.
- Early data support further in-depth research and clinical translation for PD-L1 imaging.
Why It Matters
This comprehensive review underscores the critical shift towards non-invasive, dynamic monitoring of PD-L1 expression, which is vital for optimizing cancer immunotherapy protocols. For clinicians and researchers, this means a clearer roadmap for selecting appropriate patients for immunotherapy and predicting treatment response more accurately than traditional methods. The field is moving towards integrating diagnosis and treatment (theranostics), multimodal imaging, and standardizing PD-L1-targeted molecular imaging. While significant challenges remain, particularly in clinical translation and multicenter validation, the identified tracers, including peptide-based options, offer promising avenues for developing more personalized and effective cancer treatments.
pd-l1
cancer
immunotherapy
molecular-imaging
radiotracer
review